FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

FDA D.I.S.C.O. Burst Edition: FDA approvals of Tabrecta (capmatinib) for metastatic non-small cell lung cancer and Enhertu (fam-trastuzumab deruxtecan-nxki) for HER2-mutant non-small cell lung cancer

Listen Later
Listen to a soundcast of the 8/10/2022 and 8/11/2022 FDA approvals of Tabrecta (capmatinib) for metastatic non-small cell lung cancer, and Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic non-small cell lung cancer.
...more
View all episodesView all episodes
Download on the App Store
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)By U.S. Food and Drug Administration, Center for Drug Evaluation and Research
  • 4.4
  • 4.4
  • 4.4
  • 4.4
  • 4.4

4.4

14 ratings